View Older Stories View More Recent Stories

Sep 26, 2016 01:00AM Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Sep 26, 2016 01:00AM Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Sep 20, 2016 07:03AM Regeneron (REGN), Teva Pharma (TEVA) Enter Partnership for Fasinumab Development, Commercialization
Sep 20, 2016 07:00AM Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Sep 20, 2016 07:00AM Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Sep 12, 2016 08:30AM Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Sep 1, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentations
Sep 1, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentations
Aug 29, 2016 07:12AM Regeneron (REGN), Sanofi (SNY) Announce Significant Results from Praluent Phase 3 in HeFH Patients
Aug 29, 2016 02:00AM Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Aug 29, 2016 02:00AM Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Aug 22, 2016 08:31AM Regeneron (REGN), BARDA Enter MERS Virus Antibodies Manufacturing Agreement
Aug 22, 2016 08:30AM Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Aug 4, 2016 06:30AM Regeneron Reports Second Quarter 2016 Financial and Operating Results
Aug 2, 2016 08:59AM Regeneron (REGN), Adicet Bio to Collaborate on Next-Gen Immune Cell Therapeutics
Aug 2, 2016 08:30AM Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics
Jul 18, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentation
Jul 13, 2016 08:30AM Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation
Jul 12, 2016 07:00AM Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease
Jul 8, 2016 09:30AM Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016
Jul 5, 2016 06:24AM Regeneron (REGN), Sanofi (SNY) Receive Marketing Approval for Praluent in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:01AM Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jul 5, 2016 01:00AM Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Jun 6, 2016 06:11AM Regeneron (REGN), Sanofi (SNY) Announce LIBERTY AD CHRONOS Met Primary Endpoint
Jun 6, 2016 01:01AM Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Sever...
Jun 6, 2016 01:00AM Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe A
May 31, 2016 09:03AM Regeneron (REGN) Announces Positive Interim REGN1500 Phase 2 Data in HoFH Patients
May 31, 2016 09:00AM Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
May 26, 2016 08:30AM Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
May 5, 2016 06:30AM Regeneron Reports First Quarter 2016 Financial and Operating Results
May 2, 2016 07:02AM Regeneron (REGN) Announces Statistically Significant Data from Fasinumab Phase 2/3
May 2, 2016 07:00AM Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Apr 29, 2016 09:30AM Regeneron Announces Upcoming 2016 Investor Conference Presentations
Apr 15, 2016 09:30AM Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Apr 11, 2016 04:06PM Regeneron (REGN), Intellia Therapeutics Announce Pact to Discover and Develop CRISPR/Cas Therapeutics
Apr 11, 2016 04:05PM Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Apr 1, 2016 10:00AM Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to Ring The Nasdaq Stock Market Opening Bell
Apr 1, 2016 06:57AM Regeneron (REGN), Sanofi (SNY)Announce Two Dupilumab Phase 3s Met Primary Endpoint in Atopic Dermatitis
Apr 1, 2016 01:00AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Mar 24, 2016 08:02AM Regeneron (REGN), Bayer Enter Nesvacumab + Trap Aflibercept Development Agreement for Eye Diseases
View More Recent Stories View Older Stories